
Chronic Lung Diseases

Sheikh Rayees • Inshah Din •
Gurdarshan Singh • Fayaz A. Malik
Editors

Chronic Lung Diseases

Pathophysiology and Therapeutics

Editors

Sheikh Rayees
Department of Pharmacology
University of Illinois at Chicago
Illinois, IL, USA

Inshah Din
Department of Biochemistry
University of Kashmir
Srinagar, Jammu and Kashmir, India

Gurdarshan Singh
Toxicology
CSIR-IIM
Jammu, Jammu and Kashmir, India

Fayaz A. Malik
Cancer Pharmacology
CSIR-IIM
Jammu, Jammu and Kashmir, India

ISBN 978-981-15-3733-2 ISBN 978-981-15-3734-9 (eBook)
<https://doi.org/10.1007/978-981-15-3734-9>

© Springer Nature Singapore Pte Ltd. 2020

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Singapore Pte Ltd.
The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore

Contents

1	Therapeutic Advances in the Management of Pulmonary Arterial Hypertension	1
	Suyeon Heo, Nancy Ly, Madeeha Aqil, Mohd Shahid, M. Rizwan Siddiqui, Zulfiqar Ahmad, and Mohammad Tauseef	
2	Asthma: Pathophysiology, Current Status, and Therapeutics	25
	Javeed Ahmad Bhat, Nawab John Dar, and Wajid Waheed Bhat	
3	Cystic Fibrosis: Biology and Therapeutics	61
	Pritt Verma, Vishal Kumar Vishwakarma, Shravan Kumar Paswan, Ch. V. Rao, and Sajal Srivastava	
4	Chronic Pneumonia	75
	Shravan Kumar Paswan, Vishal Kumar Vishwakarma, Chetan Rastogi, Pritt Verma, Ch. V. Rao, and Sajal Srivastava	
5	Tuberculosis	87
	Shipra Bhatt, Abhishek Gour, Gurdarshan Singh, and Utpal Nandi	
6	Lung Cancer: Pathophysiology and Current Advancements in Therapeutics	129
	Prabhu Thirusangu and V. Vigneshwaran	
7	Acute Respiratory Distress Syndrome: Therapeutics, Pathobiology, and Prognosis	143
	Vigneshwaran Vellingiri, Prabhu Thirusangu, and Inshah Din	
8	Chronic Obstructive Pulmonary Disease: An Update on Therapeutics and Pathophysiological Understanding	157
	Kaiser Jehan Peerzada	

About the Editors

Sheikh Rayees is a pharmacologist working at the University of Illinois at Chicago, USA. He completed his M.Sc. in Biotechnology at HNB Garhwal University (a Central University) followed by his doctoral degree at the prestigious CSIR-Indian Institute of Integrative Medicine and SMVDU, Jammu, India. Mr. Rayees is currently working towards understanding the biology and therapeutics of respiratory disorders like acute lung injury and acute respiratory distress syndrome. He has published several articles in leading peer-reviewed journals and has sound academic credentials. Mr. Rayees received several awards throughout his doctoral and postdoctoral research career.

Inshah Din is a research scholar working at Govt. Medical College, Srinagar. She completed her M.Sc. in Clinical Biochemistry, followed by an M.Phil. and Ph.D. in Biochemistry at the University of Kashmir. She has worked as a Junior Research fellow at the prestigious Sher-i-Kashmir Institute of Medical Sciences, Srinagar. Ms. Din has sound academic credentials and has published several research articles in peer-reviewed journals.

Gurdarshan Singh is a pharmacologist working as a principal scientist at the prestigious CSIR-Indian Institute of Integrative Medicine. He completed his M. Sc., M.Phil., and Ph.D. at Jammu University, India. Mr. Gurdarshan is currently Head of the PK-PD Toxicology Division at the CSIR-Indian Institute of Integrative Medicine, Jammu. His main research interests include evaluating new and potent drug-like molecules for their safety pharmacology, pharmacodynamic and pharmacokinetic properties. He has worked in several areas of preclinical research, e.g., asthma, hypertension, and cancer. Dr. Singh holds several patents and contributed to the development of Risorine, an antituberculosis drug and the world's first boosted-rifampicin treatment with a fixed-dose combination.

Fayaz A. Malik is an Indian cancer biologist and pharmacologist at the prestigious CSIR-Indian Institute of Integrative Medicine. He is known for his studies on investigating the regulatory mechanisms of cancer stem cells during tumor metastasis. He has also studied the identification of signaling networks that confer resistance to current anticancer therapies. The Department of Biotechnology of the Government of India awarded him the National Bioscience Award for Career Development,

one of the most coveted Indian science awards, for his contributions to biosciences in 2014. In addition, the Department of Science and Technology of the Government of India awarded him the Swarnajayanti Fellowship, one of the most prestigious fellowship awards, for his advanced research in cancer biology.